Allergan eyes middle class to boost Botox sales in Indian market

While the Botox segment is growing annually at around 20-25% in the country, Allergan India's aesthetics business is growing at 60%

Irish biopharmaceutical company Allergan is betting big on the Botox market in India, looking to more than triple its revenue in the aesthetics business from the current 15 per cent in the next three to five years.

The Nasdaq-listed company, which registered its second-quarter global revenue of $4.12 billion driven by Botox sales, is eyeing the middle class to boost sales of the Botulinum toxin-based drug in the country.  

Botox, which celebrates its 30th anniversary this year, is a drug made with neurotoxin that reduces fine lines and wrinkles by paralysing the underlying muscles. “We are eyeing the unexplored